Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Stephen Lin

Stephen Lin

Thermo Fisher Scientific USA

Title: Induced Pluripotent Stem Cells as Models of Human Disease: A Promising Approach for Studying Parkinson’s Disease

Biography

Biography: Stephen Lin

Abstract

Induced pluripotent stem cells (iPSCs) have great potential to model, and possibly treat, human ailments that have long been difficult to study in the laboratory. One example is Parkinson’s Disease (PD), a progressive neurodegenerative disorder marked by a loss of dopaminergic neurons in the brain. Because of the lack of access to disease tissue and the paucity/scarcity of good animal models, iPSC-generated neurons hold promise in the development of model systems to study PD. Beyond the core principles of generating iPSCs, a series of technologies are needed to develop these cells as disease models and therapeutics. These include the non-integrating introduction of stem cell factors, precise editing of iPSC genomes, and effective differentiation methods. Using PD as an example, I will describe a non-integrating virus delivery system that was used to generate iPSCs from Parkinson’s patients and a Transcription Activator-Like (TAL) effector nuclease technology for targeted DNA editing of those cells. I will also cover methods for studying these PD patient cells, including methods for direct differentiation of iPSCs to neural stem cells (NSCs) without the usual intermediary embryoid body and rosette formation, and downstream methods for monitoring phenotypes that are associated with PD cells. A long-term goal is to use these cells and assay technologies as a platform for interrogating small molecule compounds in order to identify drug candidates that “relieve” the phenotypes associated with PD. I will end with thoughts on challenges, but hope, of using stem cells to model and treat human diseases.